All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Kazia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

Contact the Supplier

Lead Product(s): Paxalisib

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 07, 2020

Details:

Interim analysis of Part showed median overall survival of 17.7 months, representing a clinically meaningful extension of life when compared to the 12.7 months of temozolomide.